Literature DB >> 11507034

p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53.

C T Yang1, L You, K Uematsu, C C Yeh, F McCormick, D M Jablons.   

Abstract

ONYX-015 has been reported to kill selectively tumor cells lacking functional p53. Genetic alterations of INK4a/ARF locus, which is a predominant event in malignant pleural mesothelioma, may result in loss of p14(ARF) and subsequent disruption of p53 pathway in cancer cells. In the present study, ONYX-015 was able to kill three mesothelioma cell lines (H28, H513, and 211H) with wild-type p53 but lacking p14(ARF). In contrast, MS-1 mesothelioma cells, which expressed both p53 and p14(ARF), were resistant to ONYX-015. Introducing p14(ARF) gene into the H28 cell, a mesothelioma cell without p14(ARF) expression, significantly increased the resistance of this cell line to the cytolytic effect of ONYX-015. Our results suggest that human mesotheliomas with wild-type p53 yet lacking p14(ARF) are potential candidates for ONYX-015 therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507034

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Antiviral action of the tumor suppressor ARF.

Authors:  María A García; Manuel Collado; César Muñoz-Fontela; Ander Matheu; Laura Marcos-Villar; Javier Arroyo; Mariano Esteban; Manuel Serrano; Carmen Rivas
Journal:  EMBO J       Date:  2006-09-07       Impact factor: 11.598

Review 2.  Current issues and future directions of oncolytic adenoviruses.

Authors:  Masato Yamamoto; David T Curiel
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

3.  A tumor host range selection procedure identifies p150(sal2) as a target of polyoma virus large T antigen.

Authors:  D Li; K Dower; Y Ma; Y Tian; T L Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

4.  p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.

Authors:  Sally Hopkins-Donaldson; Larisa L Belyanskaya; Ana Paula Simões-Wüst; Brigitte Sigrist; Stefanie Kurtz; Uwe Zangemeister-Wittke; Rolf Stahel
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

5.  Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.

Authors:  Junichi Okamoto; Iwao Mikami; Yuichi Tominaga; Kristopher M Kuchenbecker; Yu-Ching Lin; Dawn T Bravo; Genevieve Clement; Adam Yagui-Beltran; M Roshni Ray; Kiyoshi Koizumi; Biao He; David M Jablons
Journal:  J Thorac Oncol       Date:  2008-10       Impact factor: 15.609

Review 6.  Conditionally replicating adenoviruses for cancer treatment.

Authors:  Youssef Jounaidi; Joshua C Doloff; David J Waxman
Journal:  Curr Cancer Drug Targets       Date:  2007-05       Impact factor: 3.428

7.  Killing effect of TNF-mediated by conditionally replicating adenovirus on esophageal cancer and lung cancer cell lines.

Authors:  Yue-Quan Jiang; Zhi Zhang; Hua-Rong Cai; Hong Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

8.  An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression.

Authors:  Thao Thi Thanh Nguyen; Masato Shingyoji; Michiko Hanazono; Boya Zhong; Takao Morinaga; Yuji Tada; Hideaki Shimada; Kenzo Hiroshima; Masatoshi Tagawa
Journal:  Cell Death Dis       Date:  2021-07-02       Impact factor: 8.469

Review 9.  Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game.

Authors:  Paqui G Través; Alfonso Luque; Sonsoles Hortelano
Journal:  Mediators Inflamm       Date:  2012-12-18       Impact factor: 4.711

Review 10.  A potential therapeutic strategy for malignant mesothelioma with gene medicine.

Authors:  Yuji Tada; Hideaki Shimada; Kenzo Hiroshima; Masatoshi Tagawa
Journal:  Biomed Res Int       Date:  2013-01-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.